BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 29856777)

  • 1. A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib.
    Daneshmanesh AH; Hojjat-Farsangi M; Ghaderi A; Moshfegh A; Hansson L; Schultz J; Vågberg J; Byström S; Olsson E; Olin T; Österborg A; Mellstedt H
    PLoS One; 2018; 13(6):e0198038. PubMed ID: 29856777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
    Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
    Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells.
    Hojjat-Farsangi M; Daneshmanesh AH; Khan AS; Shetye J; Mozaffari F; Kharaziha P; Rathje LS; Kokhaei P; Hansson L; Vågberg J; Byström S; Olsson E; Löfberg C; Norström C; Schultz J; Norin M; Olin T; Österborg A; Mellstedt H; Moshfegh A
    Leukemia; 2018 Oct; 32(10):2291-2295. PubMed ID: 29725030
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeting the Receptor Tyrosine Kinase ROR1 by Small Molecules.
    Hojjat-Farsangi M; Moshfegh A; Schultz J; Norin M; Olin T; Österborg A; Mellstedt H
    Handb Exp Pharmacol; 2021; 269():75-99. PubMed ID: 34490515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling Pathway.
    Zhang Q; Wang HY; Liu X; Nunez-Cruz S; Jillab M; Melnikov O; Nath K; Glickson J; Wasik MA
    J Immunol; 2019 Oct; 203(8):2043-2048. PubMed ID: 31534006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
    Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
    Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib.
    Yu J; Chen L; Cui B; Wu C; Choi MY; Chen Y; Zhang L; Rassenti LZ; Widhopf Ii GF; Kipps TJ
    Leukemia; 2017 Jun; 31(6):1333-1339. PubMed ID: 27904138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway.
    Zheng YT; Yang HY; Li T; Zhao B; Shao TF; Xiang XQ; Cai WM
    Acta Pharmacol Sin; 2015 May; 36(5):614-26. PubMed ID: 25864651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K/AKT/GSK3ß activity.
    Fultang N; Illendula A; Chen B; Wu C; Jonnalagadda S; Baird N; Klase Z; Peethambaran B
    PLoS One; 2019; 14(5):e0217789. PubMed ID: 31150511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth.
    Chen J; Kinoshita T; Sukbuntherng J; Chang BY; Elias L
    Mol Cancer Ther; 2016 Dec; 15(12):2835-2844. PubMed ID: 27678331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silencing of Receptor Tyrosine Kinase ROR1 Inhibits Tumor-Cell Proliferation via PI3K/AKT/mTOR Signaling Pathway in Lung Adenocarcinoma.
    Liu Y; Yang H; Chen T; Luo Y; Xu Z; Li Y; Yang J
    PLoS One; 2015; 10(5):e0127092. PubMed ID: 25978653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The receptor tyrosine kinase ROR1--an oncofetal antigen for targeted cancer therapy.
    Hojjat-Farsangi M; Moshfegh A; Daneshmanesh AH; Khan AS; Mikaelsson E; Osterborg A; Mellstedt H
    Semin Cancer Biol; 2014 Dec; 29():21-31. PubMed ID: 25068995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations.
    Deniger DC; Yu J; Huls MH; Figliola MJ; Mi T; Maiti SN; Widhopf GF; Hurton LV; Thokala R; Singh H; Olivares S; Champlin RE; Wierda WG; Kipps TJ; Cooper LJ
    PLoS One; 2015; 10(6):e0128151. PubMed ID: 26030772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Small Molecule Targeting the Intracellular Tyrosine Kinase Domain of ROR1 (KAN0441571C) Induced Significant Apoptosis of Non-Small Cell Lung Cancer (NSCLC) Cells.
    Ghaderi A; Okhovat MA; Lehto J; De Petris L; Manouchehri Doulabi E; Kokhaei P; Zhong W; Rassidakis GZ; Drakos E; Moshfegh A; Schultz J; Olin T; Österborg A; Mellstedt H; Hojjat-Farsangi M
    Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor tyrosine kinase profiling of ischemic heart identifies ROR1 as a potential therapeutic target.
    Heliste J; Jokilammi A; Paatero I; Chakroborty D; Stark C; Savunen T; Laaksonen M; Elenius K
    BMC Cardiovasc Disord; 2018 Oct; 18(1):196. PubMed ID: 30342492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting ROR1/BCL2 combination targeted therapy of small cell carcinoma of the lung.
    Wang WZ; Shilo K; Amann JM; Shulman A; Hojjat-Farsangi M; Mellstedt H; Schultz J; Croce CM; Carbone DP
    Cell Death Dis; 2021 Jun; 12(6):577. PubMed ID: 34088900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism.
    Hasan MK; Ghia EM; Rassenti LZ; Widhopf GF; Kipps TJ
    Leukemia; 2021 Jun; 35(6):1621-1630. PubMed ID: 33097837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
    Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel ROR1 inhibitor ARI-1 suppresses the development of non-small cell lung cancer.
    Liu X; Pu W; He H; Fan X; Zheng Y; Zhou JK; Ma R; He J; Zheng Y; Wu K; Zhao Y; Yang SY; Wang C; Wei YQ; Wei XW; Peng Y
    Cancer Lett; 2019 Aug; 458():76-85. PubMed ID: 31125641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor tyrosine kinase-like orphan receptor 1, a target of NKX2-1/TTF-1 lineage-survival oncogene, inhibits apoptosis signal-regulating kinase 1-mediated pro-apoptotic signaling in lung adenocarcinoma.
    Ida L; Yamaguchi T; Yanagisawa K; Kajino T; Shimada Y; Suzuki M; Takahashi T
    Cancer Sci; 2016 Feb; 107(2):155-61. PubMed ID: 26661061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.